2020 American Transplant Congress
Post-Transplant Rebound and Not Baseline Anti-A Titers are Associated with Acute Antibody-Mediated Rejection in A2– to B/O Incompatible Kidney Transplantation
University of Alabama at Birmingham, Birmingham, AL
*Purpose: Decreased antigen expression among blood group A subtype 2 (A2) donor kidneys allows these organs to be considered as universal donors; under the new…2020 American Transplant Congress
Is Azathioprine the Right Choice in De Novo Lung Transplantation?
*Purpose: The antiproliferative of choice in lung transplantation (LT) remains controversial. Limited data exists on azathioprine (AZA) dose reductions or the conversion of AZA to…2020 American Transplant Congress
Comparison of Basiliximab for Induction Therapy in Kidney Transplant Recipients on Post-Operative Days 0 and 4 versus Post-Operative Days 0 and 3
Pharmacy, CHI St. Luke's Health Baylor St. Luke's Medical Center, Houston, TX
*Purpose: Current dosing recommendations for the administration of basiliximab on post-operative days (POD) 0 and 4 stem from two phase 3 renal transplant studies. Limited…2020 American Transplant Congress
Impact of Rituximab and Apheresis Techniques in Acute Rejection Rates in ABO Incompatible Living Donor Kidney Transplant
*Purpose: ABO incompatibility (ABOi) is a widespread option of living kidney donor transplantation (LKDT). However, controversies in rejection, and death-censored graft survival rates are published,…2020 American Transplant Congress
Exosomes Containing Kidney Self-Antigens (Collagen Iv, Fibronectin, Perlecan) Predicts Progression of Chronic Immune Injury in Kidney Transplant Recipients
*Purpose: We have shown that circulating exosome with lung self-antigens (SAgs) are detectable 1 year prior to chronic lung allograft dysfunction, independent of circulating antibodies.…2020 American Transplant Congress
The Banff Classification of Antibody-Mediated Rejection in Kidney Allografts: Comparison of Predictive Performance for Allograft Failure in Previous and Current Editions
*Purpose: Since its introduction in 2001, the Banff classification for antibody-mediated rejection (ABMR) has undergone significant changes, mainly by inclusion of C4d-negative ABMR in 2013…2020 American Transplant Congress
Single-Cell RNA Sequencing to Assess the Effect of IL-6 Receptor Blockade in Kidney Transplantation
University of California San Francisco, San Francisco, CA
*Purpose: Prospective randomized study of IL-6R blockade with Tocilizumab for treatment of subclinical inflammation (SCI) in renal transplantation, reveals unique profiles of resting and stimulated…2020 American Transplant Congress
Notch Signaling Inhibition via Blockade of Delta-Like Ligand 4 Prevents Co-Stimulation Blockade Resistant Allograft Rejection
Surgery and Transplantation, Emory University, Atlanta, GA
*Purpose: Co-stimulation blockade (CoB) has emerged as a promising immunosuppression strategy with the advent of Belatacept, a novel CTLA4-Ig fusion protein that blocks CD28-mediated T…2020 American Transplant Congress
Th17 Cell Inhibition in a Costimulation Blockade Based Regimen for Vascularized Composite Allotransplantation Using A Non-Human Primate Model
*Purpose: Vascularized composite allotransplantation (VCA) is challenged by the morbidity of non-specific immunosuppression required to prevent rejection. The use of highly specific biologics has not…2020 American Transplant Congress
Daratumumab for Desensitization and Antibody Mediated Rejection Treatment in Highly-HLA Sensitized Patients
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Highly-HLA sensitized (HS) patients have an immunologic barrier to transplantation. ABMR promotes graft loss and poor patient survival. Methods to reduce anti-HLA antibodies are…
- « Previous Page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- …
- 172
- Next Page »